ContributorsPublishersAdvertisers

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements

Benzinga
Benzinga
 2021-10-11
Cover picture for the article

Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK) Phase 3 trial of SRP-9001 for Duchenne muscular dystrophy. SRP-9001, being developed...

www.benzinga.com

Comments / 0

Comments / 0